Canaccord Genuity keeps Aclaris at Buy and lifts target to $13
Canaccord Genuity kept its Buy rating on Aclaris Therapeutics and raised its price target 30%, from $10 to $13, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Canaccord Genuity retained its Buy rating on Aclaris Therapeutics shares and lifted its price target from $10 to $13, a 30% increase.
The new target implies potential upside of 227.5% from the October 30 close of $3.97.
why it matters
Price target revisions like this one for small-cap companies are frequent and usually do not come with new financial results. For investors, the signal is that the analyst remains positive on the stock after raising the target, but the figure reflects the analyst's own valuation rather than a new fact about the company's business.
tags
instruments
sources
- Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to $13 from $10 — TradingView, 31 October 2026 at 00:26 UTC
- Canaccord Genuity maintains Biohaven at Buy, raises price target to $32 from $21 — TradingView, 31 October 2026 at 00:29 UTC
- Canaccord Genuity maintains Viking Therapeutics at Buy, raises price target to $118 from $106 — TradingView, 31 October 2026 at 00:37 UTC
- Canaccord Genuity maintains DexCom at Buy, raises price target to $97 from $90 — TradingView, 31 October 2026 at 00:33 UTC
- Canaccord Genuity maintains Enhanced Group at Buy, raises price target to $17 from $5 — TradingView, 31 October 2026 at 00:41 UTC
- Rosenblatt maintains Stagwell at Buy, raises price target to $13 from $10 — TradingView, 31 October 2026 at 01:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗